Neuronal activation of nucleus accumbens by local methamphetamine administration induces cognitive impairment through microglial inflammation in mice

Kusui, Yuka; Izuo, Naotaka; Tokuhara, Reika; Asano, Takashi; Nitta, Atsumi

doi:10.1016/j.jphs.2023.12.003

Cited by 1 publication

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ibudilast attenuated methamphetamine addiction in mice [102], while a high-dose ibudilast (100 mg) treatment reduced methamphetamine self-administration and craving in humans [103]. Minocycline ameliorated the cognitive impairment and synaptic dysfunction induced by methamphetamine in mice [104], while minocycline reduced the amphetamine-induced subjective rewarding effects in humans [105]. Pioglitazone (a peroxisome proliferator-activated receptor PPAR-γ agonist) attenuated behavioral sensitization during the withdrawal of methamphetamine in mice [106], while, in a clinical trial, pioglitazone reduced the craving for cocaine and enhanced white-matter integrity in cocaine abusers [107].…”

Section: Drugs For Neuroinflammationmentioning

confidence: 98%

Substance Addiction Rehabilitation Drugs

Yuan,

Jiang,

Zhang

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

The relapse rate of substance abusers is high, and addiction rehabilitation adjunct drugs need to be developed urgently. There have been numerous reports on blocking the formation of substance addiction, but studies on drugs that can alleviate withdrawal symptoms are very limited. Both the dopamine transporter (DAT) hypothesis and D3 dopamine receptor (D3R) hypothesis are proposed. DAT activators reduce the extracellular dopamine level, and D3R antagonists reduce the neuron’s sensitivity to dopamine, both of which may exacerbate the withdrawal symptoms subsequently. The D3R partial agonist SK608 has biased signaling properties via the G-protein-dependent pathway but did not induce D3R desensitization and, thus, may be a promising drug for the withdrawal symptoms. Drugs for serotoninergic neurons or GABAergic neurons and anti-inflammatory drugs may have auxiliary effects to addiction treatments. Drugs that promote structural synaptic plasticity are also discussed.

show abstract